## SamchunDang Pharm's Block Deal Withdrawal Mystery: What's Hidden Behind the 'Peak Exit' Controversy?
### [Background]
SamchunDang Pharm is a pharmaceutical and bio company focusing on developing treatments for ophthalmic diseases. In recent years, it has been accelerating the development of new drugs based on its innovative drug delivery platform technology, 'S-PASS,' garnering high expectations from the market. In particular, the development of an oral macular degeneration treatment using S-PASS technology has been a key driver of SamchunDang Pharm's stock price. However, questions about the clinical trial process and the feasibility of commercializing the technology have been consistently raised, acting as a potential backdrop for this block deal withdrawal.
In the pharmaceutical and bio industry, block deals are commonly used for fundraising or to reorganize major shareholders' equity. A successful block deal can strengthen a company's financial soundness and promote investment attraction, but it can also be withdrawn depending on market conditions or internal company circumstances. In particular, if a block deal is withdrawn when the stock price is at its peak, it can trigger a 'peak exit' controversy, acting as a factor that shrinks investment sentiment.
### [Current Situation]
On April 6, 2026, local time, SamchunDang Pharm abruptly announced the withdrawal of its block deal plan worth 250 billion won immediately after the market closed. This accounted for a significant portion of the originally planned block deal size, shocking the market. Immediately after the announcement of the block deal withdrawal, SamchunDang Pharm's stock price plummeted in after-hours trading, and online communities and stock-related bulletin boards were flooded with complaints from investors raising allegations of 'peak skimming.'
CEO Jeon In-seok of SamchunDang Pharm immediately issued an explanation. He emphasized that "the block deal withdrawal was an inevitable decision due to deteriorating market conditions and shrinking investment sentiment, and the 'peak exit' allegations are completely unfounded." He also added that insufficient explanations from external experts regarding the validity of S-PASS technology and the progress of clinical trials caused misunderstandings. However, despite CEO Jeon's explanation, investors' anxiety is not easily subsiding.
In particular, unfounded rumors that 'S-PASS is fake' are spreading, mainly through anonymous online communities, further eroding SamchunDang Pharm's credibility. These rumors raise fundamental questions about SamchunDang Pharm's core technology, acting as a factor that severely shrinks investors' investment sentiment. Currently, SamchunDang Pharm is considering legal action, but it does not seem easy to quell the spreading rumors.
### [Multi-faceted Analysis]
This SamchunDang Pharm block deal withdrawal can have serious repercussions across the pharmaceutical and bio industry, not just for one company. First, the decline in investor confidence can worsen the fundraising environment for pharmaceutical and bio companies. Innovative new drug development requires huge amounts of capital, but if investment sentiment shrinks, it may be difficult to secure funds, potentially delaying new drug development.
Second, the 'peak exit' controversy can lead to moral hazard among management. When the stock price is at its peak, management's actions to promote block deals for personal gain or to inflate the stock price by spreading false information not only harm investors but also seriously damage market order.
Third, the controversy over the authenticity of S-PASS technology can undermine the credibility of domestic pharmaceutical and bio technology. If S-PASS technology is actually ineffective or has promoted exaggerated technology, it could lead to distrust of the entire domestic pharmaceutical and bio industry. In particular, foreign investors may be reluctant to invest in domestic pharmaceutical and bio companies, which could weaken the competitiveness of the domestic pharmaceutical and bio industry.
Experts point out that this incident should strengthen the transparency of pharmaceutical and bio companies and strengthen information disclosure obligations. They also emphasize the need to secure the reliability of clinical data and strengthen the technology verification system to create an environment where investors can invest with confidence.
### [Future Prospects]
In the future, SamchunDang Pharm's stock price is expected to be greatly influenced by investors' reaction to the block deal withdrawal and the controversy over the authenticity of S-PASS technology. If SamchunDang Pharm proves the validity of S-PASS technology and transparently discloses the progress of clinical trials, it will be able to restore investor confidence and stabilize the stock price. However, if doubts about S-PASS technology are not resolved or additional negative factors occur, the stock price is likely to fall further.
Investors need to carefully monitor SamchunDang Pharm's future actions. In particular, attention should be paid to the announcement of clinical results of S-PASS technology, comparative analysis with competing drugs, and additional explanations from management. It is also important to make investment decisions based on objective information without being swayed by rumors circulating in online communities.
